Stephen J. Forman

Active 1980–2025

348
Papers
49,990
Citations
127
h-index
330
i10-index

Citations

Citations per year for Stephen J. Forman1948: 1 citations1980: 2 citations1981: 5 citations1982: 5 citations1983: 11 citations1984: 5 citations1985: 6 citations1986: 7 citations1987: 15 citations1988: 4 citations1989: 6 citations1990: 5 citations1991: 14 citations1992: 16 citations1993: 24 citations1994: 31 citations1995: 29 citations1996: 31 citations1997: 35 citations1998: 28 citations1999: 48 citations2000: 82 citations2001: 104 citations2002: 141 citations2003: 155 citations2004: 163 citations2005: 186 citations2006: 194 citations2007: 220 citations2008: 251 citations2009: 326 citations2010: 366 citations2011: 411 citations2012: 317 citations2013: 404 citations2014: 326 citations2015: 414 citations2016: 468 citations2017: 529 citations2018: 592 citations2019: 1,596 citations2020: 1,902 citations2021: 1,961 citations2022: 1,734 citations2023: 1,332 citations2024: 2,088 citations2025: 1,055 citations2026: 26 citations1949–1979: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,666 citing papers, 33.2% of this breakdownChina: 2,187 citing papers, 10.9% of this breakdownGermany: 1,361 citing papers, 6.8% of this breakdownUnited Kingdom: 1,109 citing papers, 5.5% of this breakdownItaly: 959 citing papers, 4.8% of this breakdownFrance: 777 citing papers, 3.9% of this breakdownCanada: 587 citing papers, 2.9% of this breakdownSpain: 519 citing papers, 2.6% of this breakdownAustralia: 493 citing papers, 2.4% of this breakdownNetherlands: 493 citing papers, 2.4% of this breakdownSwitzerland: 440 citing papers, 2.2% of this breakdownJapan: 425 citing papers, 2.1% of this breakdown
0%33.2%Other 20.3%

Fields

  • Medicine77.1%
  • Biochemistry, Genetics and Molecular Biology12.4%
  • Immunology and Microbiology7.3%
  • Engineering0.6%
  • Neuroscience0.6%
  • Materials Science0.6%
  • Other1.4%

Topics

  • CAR-T cell therapy research11%
  • Hematopoietic Stem Cell Transplantation4.6%
  • Immune Cell Function and Interaction4.5%
  • Acute Myeloid Leukemia Research4.4%
  • Immunotherapy and Immune Responses3.3%
  • Virus-based gene therapy research3.1%
  • Other69.1%

Coauthors

All papers

Open in search
  1. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,823

  2. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

    Authors: , , , , , , , , , , , , , - Cancer Immunology Research 2019 cited by 438

  3. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2024 cited by 295

  4. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

    Authors: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 755

  5. STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

    Authors: , , , , , , , , , , , , , , , , , , , , - Cell Metabolism 2019 cited by 367

  6. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 1,259

  7. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

    Authors: , , , , , , , , , , , - Science Translational Medicine 2020 cited by 262

  8. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 cited by 143

  9. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

    Authors: , , , , , , , , - Blood 2011 cited by 602

  10. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 470

  11. 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cell stem cell 2022 cited by 138

  12. Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain

    Authors: , , , , , , , , , , , , - Clinical Cancer Research 2017 cited by 321

  13. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies

    Authors: , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 180

  14. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary Ellen Csuka, Christopher Bredeson, Carolyn A. Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas A. Medsger, Daniel E. Furst - New England Journal of Medicine 2018 cited by 589

  15. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2017 cited by 298

  16. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages

    Authors: , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 cited by 117

  17. IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

    Authors: , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 169

  18. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 102

  19. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

    Authors: , , , , , , , , , , , , , , , - Blood 2008 cited by 719

  20. Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 230

  21. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2024 cited by 116

  22. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 330

  23. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

    Authors: , , , , , , , , - JCI Insight 2018 cited by 229

  24. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 170